The results of the PLATO trial have just been published in the Journal of Clinical Oncology (JCO). The full text of the paper by Attard et al. is available on line for any interested reader.
We had originally reported the primary results of this trial back in December 2016, when Pfizer and Astellas had initially announced that, for men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC) who were initially treated with enzalutamide (Xtandi) and then progressed, there was no survival benefit associated with the subsequent addition of abiraterone acetate (Zytiga) + prednisone.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistnt, chemotherapy-naïve, enzalutamide, mCRPC, metastatic, PLATO |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply